XML 21 R9.htm IDEA: XBRL DOCUMENT v3.20.2
CASH EQUIVALENTS AND MARKETABLE SECURITIES
 9 Months Ended
Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]  
CASH EQUIVALENTS AND MARKETABLE SECURITIES CASH EQUIVALENTS AND MARKETABLE SECURITIES
Cash Equivalents and Marketable Securities
The table below summarizes the Company’s cash equivalents and marketable securities (in thousands):
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
(Losses)		Estimated
Fair Value
September 30, 2020
Assets
Cash equivalents:
Money market funds$172,508 $— $— $172,508 
Commercial paper securities5,998 1 — 5,999 
Total178,506 1 — 178,507 
Marketable securities:
Commercial paper securities238,248 169 (19)238,398 
Corporate debt securities122,364 156 (36)122,484 
Asset-backed securities13,067 3 (4)13,066 
U.S. government-sponsored entity debt securities61,171 76 — 61,247 
Total434,850 404 (59)435,195 
Total cash equivalents and marketable securities$613,356 $405 $(59)$613,702 
December 31, 2019
Assets
Cash equivalents:
Money market funds$30,496 $— $— $30,496 
Commercial paper securities2,998 1 — 2,999 
Total33,494 1 — 33,495 
Marketable securities:
Commercial paper securities155,230 145 (7)155,368 
Corporate debt securities94,905 115 (3)95,017 
U.S. government-sponsored entity debt securities53,411 91 (9)53,493 
Total303,546 351 (19)303,878 
Total cash equivalents and marketable securities$337,040 $352 $(19)$337,373 
The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):
September 30,
2020		December 31,
2019
Maturing in one year or less$389,434 $282,046 
Maturing after one year through five years45,761 21,832 
Total$435,195 $303,878 

The Company had no realized losses of its available-for-sale securities for the three and nine months ended September 30, 2020 or 2019. The Company periodically reviews the available-for-sale investments for other-than-temporary impairment losses. No investments were other-than-temporarily impaired at either September 30, 2020 or December 31, 2019. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For available-for-sale securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company's review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company's ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these securities at September 30, 2020.